



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	March 25, 2020 June 27, 2023

SUNOSI® (solriamfetol)

LENGTH OF AUTHORIZATION: ONE YEAR

REVIEW CRITERIA:

Narcolepsy

- The patient must be 18 years of age or older; **AND**
- The patient has a diagnosis of narcolepsy according to International Classification of Sleep Disorders (ICSD-3) or Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria; **OR**
- The patient has excessive daytime sleepiness associated with narcolepsy as confirmed by documented sleep testing (e.g. polysomnography, multiple sleep latency test); **AND**
- Trial and failure of modafinil.

Obstructive Sleep Apnea (OSA)

- The patient must be 18 years of age or older; **AND**
- The patient must have a diagnosis of OSA according to ICSD-3 criteria; **OR**
- The patient has excessive daytime sleepiness associated with OSA as confirmed by documented sleep testing (e.g. polysomnography, multiple sleep latency test); **AND**
- Compliant use of continuous positive airway pressure (CPAP) at least a month prior to trial of Sunosi; **AND**
- Trial and failure to modafinil; **AND**
- Modalities to treat the underlying airway obstruction should be continued during treatment with Sunosi.

CONTINUATION OF THERAPY:

- Patient met the above criteria; **AND**
- Documentation of improved clinical response; **AND**
- Patient has not experienced any treatment-restricting adverse effects; **AND**
- Dosing is appropriate as per labeling or is supported by compendia.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 75mg (functionally scored) and 150mg tablets.